Some doctors prescribe the pill form of semaglutide off-label to assist with weight loss. “Off-label” use describes taking a drug for a purpose the FDA hasn’t approved.

Diabetes drug semaglutide is sometimes used for heart disease and weight loss. But it has a number of side effects that may make it risky to use for weight loss alone, including constipation ...

Semaglutide was initiated at a dose of 0.25 mg once weekly, and the dose was increased every 4 weeks in accordance with recommended dosing (from 0.25 mg to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg ...

The results are published today in the journal NEJM Evidence. Semaglutide is a medication that belongs to a class of drugs known as glucagon-like peptide-1, or GLP-1, receptor agonists. Sold under ...

Premature permanent discontinuation of oral semaglutide or placebo occurred in 1309 participants (27.1%) in the oral semaglutide group and in 1373 participants (28.5%) in the placebo group (Fig. S3B).

At follow-up, 12% of participants in the semaglutide group (incidence rate, 3.1 events per 100 person-years) and 13.8% of participants in the placebo group (incidence rate, 3.7 events per 100 ...

The new study, which was funded by Novo Nordisk, included about 400 patients with knee osteoarthritis, with an average age of 56, in 11 countries. About 80% of the people in the study were women ...

BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets Provided by ACCESS Newswire Jun 23, 2025, 12:05:00 AM ...

King's College London. "Semaglutide treats liver disease in two thirds of patients." ScienceDaily. ScienceDaily, 4 May 2025. <www.sciencedaily.com / releases / 2025 / 04 / 250430182815.htm>.

Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress to cirrhosis and hepatocellular carcinoma, but strategies for treating MASH are lacking ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with ...